Metrics as of 10/16/2026, 04:59 PM (Berlin time), refresh in progress.
Fortress Biotech Stock
Fortress Biotech, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lindsay A. Rosenwald
- Employees
- 78
- Market cap
- $63 M
- IPO
- 17/11/2011
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various…
Fortress Biotech stock: price history
1D
-1.1%
1W
-11.3%
1M
-23.2%
6M
-20.0%
YTD
-48.4%
1Y
-31.1%
2Y
+7.9%
5Y
-95.9%
10Y
-95.2%
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~32% stronger price swings than usual
Ask the agents about Fortress Biotech
Analyst assessment of Fortress Biotech
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 23/02/2026
Fortress Biotech stock metrics
P/E
0.58
P/B
0.37
EV/EBITDA
-0.43
RETURN ON EQUITY
-0.3%
NET MARGIN
-2.5%
DEBT/EQUITY
0.39
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
69.1%
FLOAT SHARES
23,044,207
AVG. DAILY VOLUME (30D)
261,389
Insider transactions (SEC)
Jin David
Jin David
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Fortress Biotech stock
What does Fortress Biotech do?
Fortress Biotech, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lindsay A. Rosenwald, the company employs around 78 people.
The IPO was on 17/11/2011; the stock trades on NASDAQ under the ticker FBIO.
What do analysts say about Fortress Biotech stock?
6 analysts rate the stock, the consensus is Buy (as of 23/02/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Fortress Biotech report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly 32% stronger than usual.
Does Fortress Biotech pay a dividend?
No, Fortress Biotech currently does not pay a dividend.
Which stocks are comparable to Fortress Biotech?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Fortress Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fortress Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.